A Brief Hplc Study On Dorzolamide Hydrochloride

Abstract

The Main Idea Is To Develop And Validate A Fast, Sensitive, And Accurate Reversed-phase High-performance Liquid Chromatography (RP-HPLC) Method For The Quantitative Determination Of Dorzolamide Hydrochloride (a Carbonic Anhydrase Inhibitor Used To Treat Glaucoma) In Bulk And Pharmaceutical Dosage Forms (e.g., Ophthalmic Solution). The Methodology And Parameters Are Selected According To The Drug And Desired Outcome. Chromatographic Separation Was Performed On An 18 Column, Stationary Phase, Using An Adapted Isocratic Mobile Phase Composed Of A Mixture Of Buffer (for Example, Phosphate Buffer) And Organic Solvent (for Example, Acetonitrile Or Methanol) At A Controlled Flow Rate (for Example, 1.0 ML/min). Detection Was Performed Using A UV-Vis Detector At The Maximum Absorption Wavelength Of Dorzolamide (usually Around 254nm). Percentage Recovery Studies Yielded Results Close To 100%, Confirming The High Accuracy Of The Method. The Developed RP-HPLC Method Is Suitable For Reliable And Routine Quality Control Analysis Of Dorzolamide In Pharmaceutical Preparations, Ensuring Its Quality And Therapeutic Efficacy. Dorzolamide, Often Referred To As Dorzolamide Hydrochloride (DOR), Is A Potent Topical Carbonic Anhydrase Inhibitor Developed Primarily To Avoid The Severe Systemic Side Effects Of Oral CAIs Such As Acetazolamide. It Is Used In Eye Drops To Reduce Increased Intraocular Pressure Associated With Glaucoma And Ocular Hypertension. HPLC Is A Widely Preferred Technique For Quantitative Analysis Due To Its Sensitivity, Selectivity, And Accuracy, Especially In Pharmaceutical Formulations (e.g. Eye Drops) And Biological Fluids.

Keywords